PDI 2009 ISDP LAC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 28(3): 246-251
2008
© 2008 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nessim, S. J.
Right arrow Articles by Jassal, S. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nessim, S. J.
Right arrow Articles by Jassal, S. V.

ORIGINAL ARTICLES

GASTRIC ACID SUPPRESSION AND THE RISK OF ENTERIC PERITONITIS IN PERITONEAL DIALYSIS PATIENTS

Sharon J. Nessim1,2, George Tomlinson3, Joanne M. Bargman1 and Sarbjit Vanita Jassal1,2,3

1 Division of Nephrology, University Health Network; 2 Institute of Medical Sciences, University of Toronto; 3 Division of Clinical Decision-Making & Health Care, Toronto General Research Institute, Toronto, Ontario, Canada

Correspondence to: S.V. Jassal, University of Toronto and University Health Network, 8NU-857, 200 Elizabeth St., Toronto, Ontario M5G 2C4 Canada.
vanita.jassal{at}uhn.on.ca

{diamondsuit} Objective: Peritonitis caused by enteric organisms in peritoneal dialysis (PD) patients is associated with greater morbidity and mortality than peritonitis with non-enteric organisms. One reported risk factor for enteric peritonitis (EP) is gastric acid suppression, with two small studies providing conflicting results. The objective of this study was to determine, using a larger patient population, whether gastric acid suppressants are associated with an increased risk of EP.

{diamondsuit} Patients and Methods: Using a single-center case-control design, information on episodes of EP occurring between 2003 and 2006 was collected. Control episodes were all non-enteric episodes of peritonitis that occurred during the same time interval. Proton pump inhibitor (PPI) or H2-blocker (H2B) use prior to development of peritonitis was documented.

{diamondsuit} Results: A total of 228 peritonitis episodes among 137 patients met inclusion criteria. In 32% of episodes, the causative organism was enteric. Gastric acid suppressant use was documented in 46% of episodes, with the majority on PPIs. Overall, gastric acid suppression was not associated with a higher EP risk (p = 0.17). In a post hoc analysis, PPIs were not associated with EP [odds ratio (OR) 1.3, 95% confidence interval (CI) 0.7-2.4; p = 0.42], whereas H2Bs were associated with a higher risk of EP (OR 2.9, 95% CI 1.1-7.7; p = 0.04), although the number of patients on H2Bs was small.

{diamondsuit} Conclusion: Overall, gastric acid suppression was not associated with an increased risk of peritonitis with enteric organisms. While PPI use appears to be safe for PD patients with appropriate indications, the potential risk of EP with H2Bs requires further investigation.

KEY WORDS: Enteric; gastric acid; H2-blocker; peritonitis; proton pump inhibitor.

Received 20 July 2007; accepted 16 November 2007.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2008 by Multimed Inc.